Is platelet function as measured by Thrombelastograph® monitoring in whole blood affected by platelet inhibitors?

Journal of Extra-Corporeal Technology

Volumn 37, Issue 1, 2005, Pages 43-47

  Bailey, Lori A ^a   Sistino, Joseph J ^a   Uber, Walter E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Platelet function; Platelet inhibitors; Thrombelastograph monitor

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; THROMBOCYTE SLOWING FACTOR; TIROFIBAN;

ANALYZER; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MONITOR; NORMAL HUMAN; REACTION TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

EID: 14644433027     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Topol E. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation. 1998;97:211-8.
2. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function using a modified whole blood aggregometer in PTCA patients receiving anti-GP IIb/IIIa therapy. Circulation. 1997;96:3860-6.
3. Mascelli MA, Lance ET, Damaraju L, et al. The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 1998;97:1680-8.
4. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995;26:1665-71.
5. Wagner C, Mace K, Mascelli MA, et al. pharmacodynamics of reopro (c7E3 fab): Free plasma levels determine clinical efficacy. Thromb Haemost. 1997;77:7-8.
6. Tardiff B, Jennings L, Harrington R, et al. PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001;104:399-405.
7. Gilchrist I, O'Shea J, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 2001;104:406-11.
8. Kereiakes DJ, Kleiman NS, Ambrose J, et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-42.
9. Barrett JS, Murphy G, Peerlinck K, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol & Ther. 1994;56:377-88.
10. Spiess B, Tuman K, McCarthy R, et al. Thromboelastography as an indicator of post-cardiopulmonary bypass coagulopathies. J Clin Monit. 1987;3:25-30.